The Infectious Disease Research Program was founded by Dr. Aidan Findlater and Dr. David McCullagh in 2024. The program participates in multicenter international clinical trials in the areas of bloodstream infections and pneumonia.
Current Team Members
Dr. Aidan Findlater
Physician Co-Lead
Dr. David McCullagh
Physician Co-Lead
William Dechert
Clinical Research Coordinator
Sheeba Ramachandran
Clinical Research Coordinator
Ongoing Studies
ATTACC-CAP
Community Acquired Pneumonia (CAP) is a life-threatening lung infection and a leading cause of hospitalization and mortality globally. Poor clinical outcomes are driven by the inappropriate response of the body’s inflammatory and thrombotic systems to infection, leading to thrombosis and organ dysfunction. This trial will determine if a therapeutic-dose anticoagulation with heparin will improve clinical outcomes in non-critically ill hospitalized patients.
BALANCE +
BALANCE +: A Platform Trial for Gram Negative Bloodstream Infections
This study will assess multiple treatment options for bloodstream infections caused by Gram Negative bacteria that lead to hospitalization.
SNAP
SNAP: Staphylococcus Aureus Network Adaptive Platform Trial
Bloodstream infections caused by the bacterium Staphylococcus aureus (Staphylococcus aureus bacteraemia, SAB) can be deadly. While there are many treatment options in current use, there is no clear agreement as to which of these is best. This trial aims to identify which treatment options are best.
Extraordinary Caring. Every Person. Every Time.
